Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OCULAR THERAPEUTIX, INCOCUL · Entity 273 | Chief Development Officer | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OCULAR THERAPEUTIX, INC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 254,388 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 9,990 · Balance 254,388 F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9900 to $7.1954, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9900 to $7.1954, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:44 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 9,990 | $7.05 | $70,429.50 |
DisclosureSEC source: 0001104659-26-114081 · tm2627084-2_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 254,388 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.9900 to $7.1954, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:59 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 3,035 | $10.77 | $32,686.95 |
DisclosureSEC source: 0001104659-26-101674 · tm2624096-4_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 264,378 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6429 to $10.9125, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:07 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 2,967 | $8.20 | $24,329.40 |
DisclosureSEC source: 0001104659-26-067483 · tm2615856-3_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,141 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1549 to $8.2550, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 23:19 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 2,810 | $8.28 | $23,266.80 |
DisclosureSEC source: 0001104659-26-019804 · tm267255-3_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,108 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2300 to $8.3600, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 240,932 | $0.00 Strike: $11.82 | $0.00 |
DisclosureSEC source: 0001104659-26-001291 · tm261962-5_4seq1.xml · derivative · entry 2 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,932 Underlying: Common Stock · 240,932 shares Expires 2036-01-01 F3 · derivative.exercise_date: Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:05 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 79,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-001291 · tm261962-5_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,918 F1 · shares: On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. F2 · balance_after: Includes 1,373 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on December 31, 2025. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 21:01 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 3,007 | $12.02 | $36,144.14 |
DisclosureSEC source: 0001104659-25-116422 · tm2532258-2_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 191,433 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.74 to $12.28, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 21:13 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 9,653 | $11.03 | $106,472.59 |
DisclosureSEC source: 0001104659-25-097165 · tm2528026-2_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,440 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.0697, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 22:44 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 3,011 | $12.04 | $36,252.44 |
DisclosureSEC source: 0001104659-25-084117 · tm2524438-4_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,093 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.89 to $12.1548, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| May 23, 2025 Filed May 27, 2025 21:40 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 2,974 | $7.17 | $21,323.58 |
DisclosureSEC source: 0001104659-25-053091 · tm2516174-3_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,104 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.28, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 23:24 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 3,009 | $6.87 | $20,671.83 |
DisclosureSEC source: 0001104659-25-017564 · tm257640-2_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,078 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2025. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.78 to $6.97, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 12:51 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | SaleCommon Stock | 2,897 | $9.01 | $26,101.97 |
DisclosureSEC source: 0001104659-24-123413 · tm2429613-3_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,087 F1 · kind: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2024. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.88 to $9.10, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:21 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.31 | $0.00 |
DisclosureSEC source: 0001104659-24-106328 · tm2425639-4_4seq1.xml · derivative · entry 2 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-10-01 F2 · derivative.exercise_date: Vests over four years, with 1/48 of the shares vesting monthly beginning on November 1, 2024. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:21 UTC | OCULAR THERAPEUTIX, INC OCUL · Entity 273 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-106328 · tm2425639-4_4seq1.xml · nonDerivative · entry 1 Kaiser Peter · CIK 0002011869 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,984 F1 · shares: On October 2, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on October 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.